Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

• Conditions: Metastatic Colorectal Cancer

• Registration Number: NCT03286738
• Lead Sponsor: Joong Bae Ahn

Brief Summary

* Registry

* Multicenter, prospective observational study

* Observe adverse events and efficacy in recruited patients for 3 years under real world settings.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-11
• Study First Submitted: 2017-09-12
• Study First Submitted QC: 2017-09-13
• Study First Posted: 2017-09-18
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-21
• Last Update Posted: 2021-04-22
• Primary Completion: 2021-12
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1800

Inclusion Criteria

1. Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment
2. Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection®

Exclusion Criteria

1. Patients with conditions in which any study drug is contraindicated per the respective approved label.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
percentage of use FOLFIRI regimen and target agents	through study completion, 3 years

Trial Locations

Locations (1)

Yonsei University Health System, Severance Hospital; 🇰🇷 Seoul, Korea, Republic of